A new clinical trial for the investigational compound GSK2402968 (formerly PRO051) was posted to www.clinicaltrials.gov
today. This study, GSK protocol # DMD114118, will assess the pharmacokinetics, safety and tolerability of GSK2402968 after a single administration, at escalating dose levels, in non-ambulatory boys with DMD who have a dystrophin gene mutation amenable to an exon 51 skip.
The inclusion/exclusion criteria, study endpoints and investigator locations are posted on the website.
As the clinical development program advances, further clinical trials will be posted to www.clinicaltrials.gov
. We will alert you when this happens.
Questions which are not answered by the information on www.clinicaltrials.gov
should be sent to:
John E. Kraus, MD, PhD Padraig Wright, MD, PhD